Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research on MSN

Here's Why GSK (GSK) is a Strong Momentum Stock

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
GSK plc’s strong oncology growth, highlighted by Ojjaara sales and an upgraded 2025 outlook, earns a continued 'Buy' rating.
If you are on the fence about what to do with your GSK shares, you are not alone. The stock has seen some interesting moves ...
There’s a lot of froth in the stock market right now. Yet at the same time, there are also a lot of bargains for long-term investors. The post While there are bubbles in the stock market, this sector ...
Zacks Investment Research on MSN

Why GSK (GSK) is a Top Growth Stock for the Long-Term

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...
AstraZeneca (AZN) stock and GSK (GSK) stock gain as the U.K. and U.S. are reportedly clining in on a major drug pricing deal. Read more here.
Shares in FTSE 100 giant AstraZeneca (LSE:AZN) are up 22% in three months, but is it a good time to buy? The post Up 22% in 3 months! Should investors consider buying shares in this FTSE 100 pharma ...
GSK (LSE:GSK) shares have delivered a solid run recently, gaining 9% over the past month and 14% in the past 3 months. Investors are keeping an eye on what is driving this positive momentum and how ...
GSK chief executive Emma Walmsley is to step down after more than eight years running the pharmaceuticals giant.
Shares of GSK rallied on Monday after the U.K. pharmaceutical giant turned to an insider to become its next CEO. Luke Miels, chief commercial officer, will take the reigns on Jan. 1 from Emma Walmsley ...